DAB389IL-2: Started a Phase I/II trial

Seragen Inc. (SRGN) Product: DAB389IL-2 interleukin-2 receptor-targeted fusion toxin Indication: HIV-positive patients with a CD4 lymphocyte count of 300 to 600/mm3 who have not had opportunistic infe...